Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Witte, T. de

Refine Results

Resource Type

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(21 - 40 of 77)

Pages

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT
RIC vs. MAC followed by allogeneic stem cell transplantation for patients with MDS or secondary AML: A prospective, randomized phase III study of the CMWP of the EBMT (RICMAC-Trial)
Clearance of Minimal Residual Disease (MRD) in patients with 17p-CLL after Allogeneic HCT: Results of the Non-interventional Study of EBMT & ERIC
Allogeneic stem cell transplantation for MDS patients more than 70 years of age. A report of MDS subcommittee of CMWP of EBMT
Prospective analysis of prognostic pre-transplant factors in MDS primarily treated by allogeneic hematopoietic stem cell transplantation: a study on behalf of the MDS subcommittee of the Chronic Malignancies Working Party of the EBMT
Role of allogeneic SCT in low risk MDS: A Retrospective Study on Behalf of the CMWP of the EBMT
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial
Characterization of acute myeloid leukemia based on levels of global hydroxymethylation
CHARACTERIZATION OF GLOBAL HYDROXYMETHYLATION LEVELS IN AML
Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial

Pages